Table 2.
Treatment characteristics (n = 33)
| Total (n = 33) | |
|---|---|
| Number of neoadjuvant cycles, n (%) | |
| No surgery | 6 (18.2) |
| 3 cycles | 18 (54.5) |
| 4 cycles | 4 (12.1) |
| 6 cycles | 5 (15.2) |
| Surgical result, n (%) | |
| No surgery | 6 (18.2) |
| CC0 (no residual disease) | 19 (57.6) |
| CC1 (<2.5 mm) | 2 (6.1) |
| CC2a (2.5-10 mm) | 3 (9.1) |
| CC2b (>10 mm) | 3 (9.1) |
| Paclitaxel regimen, n (%) | |
| Once a week Once every three weeks | 23 (69.7) 10 (30.3) |
| Median number of pembrolizumab cycles, (IQR) | 11 (7-12) |
| Median time between NACT and surgerya, days (IQR) | 38 (32-45) |
| Median time between surgery and adjuvant therapya, days (IQR) | 32 (28-36) |
| Chemotherapy treatment completed (six cycles), n (%) | |
| Yes | 27 (81.8) |
| No | 6 (18.2) |
| Reasons for discontinuation of chemotherapy, n (%) | |
| Disease progression | 1 (3.0) |
| No response to therapy | 4 (12.1) |
| Adverse events | 1 (3.0) |
| Pembro treatment completed (including maintenance phase), n (%) | |
| Yesb | 17 (51.5) |
| No | 16 (48.5) |
| Reasons for discontinuation of pembro, n (%) | |
| Disease progression during pembro monotherapy | 13 (39.4) |
| No response to therapy | 1 (3.0) |
| Adverse event | 2 (6.1) |
| Carboplatin | |
| RDI all cycles (%), median (IQR) | 90 (70-90) |
| Number of cycles, mean (sd) | 5.5 (1.0) |
| Dose reduction, n (%) | 14 (42.4) |
| Dose delay (>7 days), n (%) | 14 (42.4) |
| Early discontinuation (<6 cycles), n (%) | 7 (21.2) |
| Paclitaxel | |
| RDI all cycles (%) | 80 (70-90) |
| Number of cycles, mean (sd) | 5.5 (1.0) |
| Dose reduction, n (%) | 19 (57.6) |
| Dose delay (>7days), n (%) | 19 (57.6) |
| Early discontinuation (<6 cycles), n (%) | 7 (21.2) |
| PARP inhibition (front-line maintenance treatment), n (%) | |
| Yesc | 3 (9.1) |
NACT neoadjuvant chemotherapy, RDI relative dose intensity.
aSix patients who did not undergo cytoreductive surgery were excluded. bIn three patients, one pembrolizumab cycle in the maintenance phase was omitted because of the COVID-19 pandemic. cOne patient with a somatic BRCA1 mutation did not receive maintenance PARP inhibition in the frontline setting, as she was treated before olaparib was incorporation in Dutch guidelines and reimbursed in 2019.